Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SWTX SpringWorks Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SWTX
Price (delayed)
$46.98
Market cap
$3.54B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.41
Enterprise value
$3.48B
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks
Highlights
SWTX's EPS is up by 34% YoY and by 2% from the previous quarter
The net income has grown by 25% YoY
SWTX's quick ratio is down by 39% year-on-year but it is up by 13% since the previous quarter
SWTX's debt is up by 13% year-on-year but it is down by 7% since the previous quarter
SpringWorks Therapeutics's equity has decreased by 26% YoY and by 13% QoQ
Key stats
What are the main financial stats of SWTX
Market
Valuations
Earnings
Shares outstanding
75.32M
Market cap
$3.54B
Enterprise value
$3.48B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.43
Price to sales (P/S)
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.85
Revenue
$219.67M
Gross profit
$204.8M
Operating income
-$264.74M
Net income
-$253.93M
EBIT
-$252.94M
EBITDA
-$247.19M
Free cash flow
-$169.33M
Per share
Balance sheet
Liquidity
EPS
-$3.41
EPS diluted
-$3.41
Free cash flow per share
-$2.26
Book value per share
$5.57
Revenue per share
$2.93
TBVPS
$6.75
Total assets
$505.36M
Total liabilities
$87.96M
Debt
$7.39M
Equity
$417.4M
Working capital
$274.05M
Debt to equity
0.02
Current ratio
4.33
Quick ratio
4
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-112.5%
Gross margin
93.2%
Net margin
-115.6%
Operating margin
-120.5%
Return on assets
-43.8%
Return on equity
-51.1%
Return on invested capital
-58.1%
Return on capital employed
-59.8%
Return on sales
-115.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SWTX stock price
How has the SpringWorks Therapeutics stock price performed over time
Intraday
-0.02%
1 week
0.04%
1 month
1.12%
1 year
25.18%
YTD
30.03%
QTD
6.46%
Financial performance
How have SpringWorks Therapeutics's revenue and profit performed over time
Revenue
$219.67M
Gross profit
$204.8M
Operating income
-$264.74M
Net income
-$253.93M
Gross margin
93.2%
Net margin
-115.6%
SWTX's operating margin has soared by 91% YoY and by 17% from the previous quarter
SWTX's net margin has surged by 91% year-on-year and by 14% since the previous quarter
The operating income has grown by 26% YoY and by 4.8% from the previous quarter
The net income has grown by 25% YoY
Price vs fundamentals
How does SWTX's price correlate with its fundamentals
Growth
What is SpringWorks Therapeutics's growth rate over time
Valuation
What is SpringWorks Therapeutics stock price valuation
P/E
N/A
P/B
8.43
P/S
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.85
SWTX's EPS is up by 34% YoY and by 2% from the previous quarter
The P/B is 56% above the 5-year quarterly average of 5.4 and 48% above the last 4 quarters average of 5.7
SpringWorks Therapeutics's equity has decreased by 26% YoY and by 13% QoQ
SWTX's P/S is 19% below its last 4 quarters average of 19.7
SpringWorks Therapeutics's revenue has increased by 15% from the previous quarter
Efficiency
How efficient is SpringWorks Therapeutics business performance
SWTX's ROS has soared by 91% YoY and by 15% from the previous quarter
The company's return on invested capital rose by 31% YoY but it fell by 4.1% QoQ
SWTX's ROA is up by 24% YoY but it is down by 4.8% from the previous quarter
The ROE has grown by 23% YoY but it has contracted by 6% from the previous quarter
Dividends
What is SWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SWTX.
Financial health
How did SpringWorks Therapeutics financials performed over time
SWTX's quick ratio is down by 39% year-on-year but it is up by 13% since the previous quarter
The company's current ratio fell by 37% YoY but it rose by 14% QoQ
SWTX's debt is 98% smaller than its equity
The debt to equity has soared by 100% YoY
SpringWorks Therapeutics's equity has decreased by 26% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.